Zacks Investment Research upgraded shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) from a sell rating to a hold rating in a report released on Tuesday.

According to Zacks, “Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. “

Other analysts also recently issued research reports about the stock. Wedbush reiterated an ourperform rating and issued a $39.00 price objective on shares of Lexicon Pharmaceuticals in a report on Monday, August 7th. Cowen and Company reissued a hold rating on shares of Lexicon Pharmaceuticals in a research note on Tuesday, August 1st. Needham & Company LLC reissued a buy rating and issued a $21.00 price target on shares of Lexicon Pharmaceuticals in a research note on Sunday, September 17th. Finally, BidaskClub cut shares of Lexicon Pharmaceuticals from a sell rating to a strong sell rating in a research note on Thursday, August 10th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $28.75.

Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) opened at $9.65 on Tuesday. The company has a quick ratio of 1.65, a current ratio of 1.66 and a debt-to-equity ratio of 1.09. Lexicon Pharmaceuticals has a 1-year low of $8.07 and a 1-year high of $18.00.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.07. The company had revenue of $26.94 million during the quarter, compared to the consensus estimate of $27.97 million. Lexicon Pharmaceuticals had a negative net margin of 165.69% and a negative return on equity of 111.68%. Lexicon Pharmaceuticals’s quarterly revenue was down 2.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.35) EPS. equities analysts forecast that Lexicon Pharmaceuticals will post -1.45 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Lexicon Pharmaceuticals, Inc. (LXRX) Upgraded at Zacks Investment Research” was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US and international copyright and trademark laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/11/18/lexicon-pharmaceuticals-inc-lxrx-upgraded-at-zacks-investment-research.html.

In related news, Director Public Equities L.P. Invus acquired 575,946 shares of the stock in a transaction that occurred on Tuesday, November 14th. The stock was purchased at an average price of $9.64 per share, with a total value of $5,552,119.44. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Lonnel Coats acquired 30,000 shares of the stock in a transaction that occurred on Friday, September 15th. The shares were bought at an average cost of $12.54 per share, with a total value of $376,200.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 945,353 shares of company stock valued at $9,304,953 in the last ninety days. 5.77% of the stock is currently owned by corporate insiders.

Large investors have recently bought and sold shares of the stock. Parametric Portfolio Associates LLC purchased a new position in shares of Lexicon Pharmaceuticals during the 2nd quarter worth approximately $182,000. Cubist Systematic Strategies LLC purchased a new position in shares of Lexicon Pharmaceuticals during the 3rd quarter worth approximately $149,000. First Mercantile Trust Co. boosted its position in shares of Lexicon Pharmaceuticals by 11.2% during the 2nd quarter. First Mercantile Trust Co. now owns 12,212 shares of the biopharmaceutical company’s stock worth $201,000 after purchasing an additional 1,227 shares during the period. Cim Investment Mangement Inc. purchased a new position in shares of Lexicon Pharmaceuticals during the 2nd quarter worth approximately $262,000. Finally, Pacad Investment Ltd. purchased a new position in shares of Lexicon Pharmaceuticals during the 2nd quarter worth approximately $265,000.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.